Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis
- PMID: 21528055
- PMCID: PMC3080717
- DOI: 10.3748/wjg.v17.i14.1831
Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis
Abstract
Aim: To identify factors predicting the clinical response of ulcerative colitis patients to granulocyte-monocyte apheresis (GMA).
Methods: Sixty-nine ulcerative colitis patients (39 F, 30 M) dependent upon/refractory to steroids were treated with GMA. Steroid dependency, clinical activity index (CAI), C reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), values at baseline, use of immunosuppressant, duration of disease, and age and extent of disease were considered for statistical analysis as predictive factors of clinical response. Univariate and multivariate logistic regression models were used.
Results: In the univariate analysis, CAI (P = 0.039) and ESR (P = 0.017) levels at baseline were singled out as predictive of clinical remission. In the multivariate analysis steroid dependency [Odds ratio (OR) = 0.390, 95% Confidence interval (CI): 0.176-0.865, Wald 5.361, P = 0.0160] and low CAI levels at baseline (4 < CAI < 7) (OR = 0.770, 95% CI: 0.425-1.394, Wald 3.747, P = 0.028) proved to be effective as factors predicting clinical response.
Conclusion: GMA may be a valid therapeutic option for steroid-dependent ulcerative colitis patients with mild-moderate disease and its clinical efficacy seems to persist for 12 mo.
Keywords: Granulocyte-monocyte apheresis; Long-term follow-up; Predictive factors; Steroid therapy; Ulcerative colitis.
Figures
Similar articles
-
Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis.Dig Liver Dis. 2006 Jun;38(6):389-94. doi: 10.1016/j.dld.2005.12.005. Epub 2006 Mar 29. Dig Liver Dis. 2006. PMID: 16569521
-
In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients.Dig Liver Dis. 2008 Sep;40(9):731-6. doi: 10.1016/j.dld.2008.02.012. Epub 2008 Apr 2. Dig Liver Dis. 2008. PMID: 18387860
-
Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis.World J Gastroenterol. 2005 Nov 28;11(44):7001-6. doi: 10.3748/wjg.v11.i44.7001. World J Gastroenterol. 2005. PMID: 16437606 Free PMC article. Clinical Trial.
-
Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis.BMJ Open. 2021 May 19;11(5):e042374. doi: 10.1136/bmjopen-2020-042374. BMJ Open. 2021. PMID: 34011580 Free PMC article.
-
Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives.Transfus Apher Sci. 2010 Oct;43(2):227-9. doi: 10.1016/j.transci.2010.07.023. Transfus Apher Sci. 2010. PMID: 20817610 Review.
Cited by
-
A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis.Clin Transl Gastroenterol. 2018 Jul 6;9(7):170. doi: 10.1038/s41424-018-0037-0. Clin Transl Gastroenterol. 2018. PMID: 29977035 Free PMC article.
-
Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease.World J Gastroenterol. 2014 Dec 7;20(45):17155-62. doi: 10.3748/wjg.v20.i45.17155. World J Gastroenterol. 2014. PMID: 25493030 Free PMC article.
-
Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective.World J Gastroenterol. 2021 Mar 14;27(10):908-918. doi: 10.3748/wjg.v27.i10.908. World J Gastroenterol. 2021. PMID: 33776362 Free PMC article. Review.
-
Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry.J Gastroenterol. 2012 Apr;47(4):359-65. doi: 10.1007/s00535-011-0499-2. Epub 2011 Nov 23. J Gastroenterol. 2012. PMID: 22105230
-
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?Biologics. 2019 Apr 9;13:23-31. doi: 10.2147/BTT.S179006. eCollection 2019. Biologics. 2019. PMID: 31114154 Free PMC article.
References
-
- Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429. - PubMed
-
- Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260. - PubMed
-
- Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21–28. - PubMed
-
- Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001;7 Suppl 1:S17–S22. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous